Linezolid glucose injection is a synthetic oxazolidinone antibiotic. It is a bacterial protein synthesis inhibitor. It acts on the 50S ribosomal subunit of bacteria to prevent the formation of 70S initial complexes, thereby inhibiting the synthesis of bacterial protein. It is used to treat infections caused by gram-positive (G) cocci, including suspected or confirmed hospital-acquired pneumonia (HAP) caused by MRSA, community-acquired pneumonia (CAP), complex skin or skin and soft tissue infections (SSTI), and resistant Vancomycin enterococcus infection, etc., and its safety is good, and it can be used from newborn babies to elderly patients, and its clinical application range is relatively wide. Linezolid glucose injection has more clinical application data and guideline recommendations, and is highly recognized by physicians.

XY-LN: Originally developed by Pfizer, it is the only drug for the treatment of vancomycin infection, which fills the gap in the few drugs that solve the clinical drug resistance problem (this variety has been declared to the SFDA for review).